EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Managing NDSRIs in Pharmaceuticals: Integrating Structural Risk Assessment and Mitigation Strategies

Wisut Wichitnithad, Pornpoom Angsuwattana, Binbin Yu, Worathat Thitikornpong, Pornchai Rojsitthisak

ACS Chemical Health & Safety · 25.05.2026 · 33 (3) · 350-370

DOI: 10.1021/acs.chas.6c00012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Health & Safety, online erschienen am 22.04.2026. Verfasst von Wisut Wichitnithad und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chulalongkorn University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of nitrosamine drug-substance-related impurities (NDSRIs) has presented a complex and evolving challenge to pharmaceutical manufacturing and regulatory oversight. Unlike traditional nitrosamines, NDSRIs may form through multiple pathways involving active pharmaceutical ingredients (APIs), synthetic intermediates, excipients, packaging components, and degradation processes. This review integrates the current understanding of NDSRI formation with implications for pharmaceutical process development, impurity control, and lifecycle risk mitigation. Key structural alerts, including secondary and tertiary amines, piperazines, and hydrazines, are discussed in relation to nitrosating agents, oxidative stressors, and solid-state properties. Special attention is given to precursor-derived and degradation-induced nitrosation, polymorphic variability, and moisture sensitivity, all of which influence NDSRI formation during both the synthesis and formulation stages. Case examples in high-risk therapeutic classes (e.g., antihypertensive drugs, antimicrobial agents, and antidiabetic agents) illustrate diverse routes of NDSRI formation and control opportunities. Mitigation strategies are outlined, including synthetic route design, excipient selection and precursor control, crystallization optimization, and storage conditions, all framed within a tiered, life-cycle-based risk management model aligned with ICH Q9(R1), ICH Q10, and the Carcinogenic Potency Categorization Approach (CPCA). The role of in silico tools, including structure–activity relationships (SAR), quantitative SAR (QSAR), and machine learning (ML), is emphasized in supporting nitrosation risk prediction and acceptable intake (AI) estimation.

Förderung

  • Chulalongkorn University

Zitieren

APA

Wichitnithad, W., Angsuwattana, P., Yu, B., Thitikornpong, W., & Rojsitthisak, P. (2026). Managing NDSRIs in Pharmaceuticals: Integrating Structural Risk Assessment and Mitigation Strategies. ACS Chemical Health & Safety, 33(3), 350-370. https://doi.org/10.1021/acs.chas.6c00012

Vancouver

Wichitnithad W, Angsuwattana P, Yu B, Thitikornpong W, Rojsitthisak P. Managing NDSRIs in Pharmaceuticals: Integrating Structural Risk Assessment and Mitigation Strategies. ACS Chemical Health & Safety. 2026;33(3):350-370. doi:10.1021/acs.chas.6c00012

BibTeX
@article{Wichitnithad2026,
  author = {Wichitnithad, Wisut and Angsuwattana, Pornpoom and Yu, Binbin and Thitikornpong, Worathat and Rojsitthisak, Pornchai},
  title = {Managing NDSRIs in Pharmaceuticals: Integrating Structural Risk Assessment and Mitigation Strategies},
  journal = {ACS Chemical Health & Safety},
  year = {2026},
  volume = {33},
  number = {3},
  pages = {350--370},
  doi = {10.1021/acs.chas.6c00012}
}
Kostenlos starten →